GT Biopharma Inc
GTBP
Company Profile
Business description
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.
Contact
315 Montgomery Street
10th Floor
San FranciscoCA94104
USASector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
1
Stocks News & Analysis
stocks
The ultimate investing hack: dividend growth stocks
Finding companies built for lasting dividend growth.
stocks
Is the data centre party over for Goodman?
Global spending spree on data centres could mean a declining return on invested capital.
stocks
Is AUB an opportunity after shares plunge 17%?
After a takeover bid was withdrawn shares dropped to below the pre-bid price.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,894.20 | 5.90 | 0.07% |
| CAC 40 | 8,087.42 | 12.81 | 0.16% |
| DAX 40 | 23,693.71 | 17.15 | -0.07% |
| Dow JONES (US) | 47,853.85 | 379.39 | 0.80% |
| FTSE 100 | 9,692.07 | 9.73 | -0.10% |
| HKSE | 25,760.73 | 334.32 | -1.28% |
| NASDAQ | 23,466.35 | 52.68 | 0.22% |
| Nikkei 225 | 49,864.68 | 561.23 | 1.14% |
| NZX 50 Index | 13,582.54 | 79.77 | 0.59% |
| S&P 500 | 6,853.53 | 24.16 | 0.35% |
| S&P/ASX 200 | 8,595.20 | 4.90 | 0.06% |
| SSE Composite Index | 3,878.00 | 19.71 | -0.51% |